Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches the NextSeq™ 500 Sequencing System

Published: Thursday, January 16, 2014
Last Updated: Wednesday, January 15, 2014
Bookmark and Share
Transformative addition to industry-leading portfolio brings whole genome sequencing to the desktop.

Illumina, Inc. has announced the immediate availability of a transformative addition to its industry-leading next-generation sequencing portfolio with the launch of the NextSeq 500 System.

The new sequencer packs high-throughput performance into an affordable desktop form factor, enabling researchers to perform the most popular sequencing applications in less than a day. The NextSeq 500 System is priced at $250,000.

“Illumina’s sequencing portfolio is the most comprehensive in the world, and the addition of the NextSeq 500 System furthers this distinction by enabling next-generation sequencing to become an everyday tool,” said Jay Flatley, CEO of Illumina. “The NextSeq 500 was reimagined from the ground up and uses technology breakthroughs in optics, fluidics and chemistry to bring high throughput power to the desktop at a significantly reduced cost.”

NextSeq 500 System - Flexible Power
The NextSeq 500 System delivers the power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, effectively transforming a broad range of high-throughput applications into affordable, everyday research tools. Its push-button operation delivers a one-day turnaround for a number of popular sequencing applications, including one whole human genome and up to 16 exomes, up to 20 non-invasive prenatal testing samples, up to 20 transcriptomes, up to 48 gene expression samples and up to 96 targeted panels. With its streamlined informatics, sequencing data can be run through a range of open source or commercial pipelines or instantly transferred, analyzed, and stored securely in BaseSpace® or the new BaseSpace® OnSite for researchers needing an on premises solution.

Users also have the flexibility to switch to lower throughput sequencing as needed, and while other platforms require several pieces of specialized equipment, the NextSeq 500 System integrates cluster generation and sequencing into a single instrument. Data is generated in as little as 12 hours for a 75 cycle sequencing run and less than 30 hours for paired 150 cycle reads.

The new system is supported by the full suite of Illumina sample preparation and target enrichment solutions, offering library compatibility across the entire Illumina sequencing portfolio. Its configurable output supports a wide range of applications and sample sizes with the accuracy of Illumina sequencing by synthesis (SBS) technology.

Unrivaled Sequencing Portfolio
Illumina’s sequencing portfolio delivers the broadest range of applications, with standard workflow and chemistries across platforms. Illumina’s systems are the production platform of choice for all major genome centers and leading institutions around the world:
• HiSeq X™ Ten is the world’s first system to deliver full coverage genomes for less than $1,000. Purpose-built for large-scale human whole genome sequencing, it enables population-scale sequencing of tens of thousands of samples per year with high-quality, high-coverage SBS data, delivering a comprehensive catalog of human variation within and outside coding regions.
• HiSeq® 2500 System is the proven high-throughput powerhouse that enables efficient sequencing and large-scale studies at low operating costs. In Q2 2014, with the addition of recently announced 1T kit capabilities, many currently installed HiSeq systems will be capable of producing 1 terabase of sequencing data and run up to 10 whole human genomes in six days.
• MiSeq® System delivers low-complexity, targeted, small-genome sequencing for individual scientists who need a higher-quality view than they can get with capillary electrophoresis, PCR, or any competing offering.
• MiSeqDx™ System, designed specifically for clinical laboratories, is the first FDA-cleared in vitro diagnostic next-generation sequencing system.

Availability
The NextSeq 500 System is now shipping.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Applauds FDA’s Issuance of Draft Guidances
Company has supported the FDA in their efforts to provide a flexible and streamlined approach to the oversight of NGS diagnostic test.
Friday, July 08, 2016
Illumina Announces Agricultural Greater Good Initiative Grant
The grant program is designed to help identify measures that can increase crop yields and improve livestock welfare and productivity to alleviate poverty and hunger in the developing world.
Tuesday, June 14, 2016
ArcherDX, Illumina Launch Collaboration
Agreement to bring multiple Archer® assays through the FDA approval process.
Tuesday, May 31, 2016
Illumina Registers MiSeqDx System in South Korea
Regulatory milestone clears path for clinical laboratories to use Illumina NGS technology.
Tuesday, May 10, 2016
Illumina Files Patent Infringement Suit against Genoma SA
Company has announced that it has filed a patent infringement suit against Genoma SA in the Switzerland for Infringement of NIPT Patents.
Friday, April 22, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software
Company has announced that it has applied the CE mark to expand the use of VeriSeq NIPT analysis software in clinical laboratories.
Thursday, February 25, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Genomics England, Illumina Enter Bioinformatics Partnership
Illumina, and Genomics England have announced a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation.
Thursday, February 11, 2016
Illumina Signs Multiple Biobank Deals
Company has signed four deals to advance personalized medicine and improve health care.
Tuesday, February 09, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Appoints Dr. Frances Arnold to its Board of Directors
Dr. Arnold is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Sunday, January 31, 2016
Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Illumina, Inc. has announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Thursday, January 28, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!